SRp30b Inhibitors

The compounds listed above serve as indirect inhibitors of SRSF3 (SRp30b), primarily through their interaction with the spliceosome, particularly the SF3b complex. SRSF3 is critical in the splicing of pre-mRNA, influencing both constitutive and alternative splicing processes. The alteration of spliceosome function through these inhibitors can therefore indirectly affect the activity of SRSF3.

The majority of these compounds, including Pladienolide B, Meayamycin, and E7107, function by binding to the SF3b complex, a critical component of the spliceosome. This binding disrupts the normal recognition of splice sites, leading to aberrant splicing. Since SRSF3 is involved in the selection and recognition of splice sites, its function can be indirectly altered by these compounds. This disruption is key to understanding how spliceosome inhibitors can influence the activity of various SR proteins, including SRSF3. Natural products like FR901464, Spliceostatin A, and Herboxidiene, along with synthetic derivatives such as Sudemycin D6, demonstrate a wide range of chemical structures capable of affecting spliceosome function. These inhibitors showcase the complexity of targeting splicing as a means to modulate protein function. Indirect inhibitors like Indisulam and Chloroquinoxaline Sulfonamide, initially developed for other purposes, also highlight the interconnected nature of cellular processes, where altering one component can have cascading effects on others.